Dr. Steven L. Allen

Richard Furman is a Hematologist and an Oncologist in New York, New York. Dr. Furman is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, Bone Marrow Aspiration, and Lymphadenectomy.

Jonathan Kolitz, MD, FACP, is Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. An expert in malignant hematology, he is the System Head for Malignant Hematology for the Northwell Health Cancer Institute where he guides the clinical care and research activities of faculty and fellows. Board certified in Internal Medicine, Hematology and Medical Oncology, Dr. Kolitz has been a member of the Leukemia Core Committee of the CALGB/Alliance since 1993. He has focused on the development, conduct and publication of innovative clinical trials for the treatment of hematologic malignancies, especially acute leukemia. He has been principal investigator for numerous novel drug trials and has been involved in multiple national and international collaborations, leading to over 200 publications. As an attending physician at the Monter Cancer Center, Dr. Kolitz focuses on providing compassionate, personalized, evidence-based care. Dr. Kolitz earned his medical degree from the Yale University School of Medicine. He trained in Internal Medicine at North Shore University Hospital and Hematology and Medical Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Kolitz is an active member of the American Society of Hematology, American Society of Clinical Oncology and the American College of Physicians. Dr. Kolitz is rated as an Elite provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Leukemia, Chronic B-Cell Leukemia (CBCL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

The Chronic Lymphocytic Leukemia (CLL) Research and Treatment Program has become a landmark for CLL patients worldwide. Dr. Kanti Rai has been involved in diagnosing and treating CLL for almost 40 years and the staging system that bears his name came out of his early breakthrough research. His particular areas of interest are: natural history of CLL, improving prognostic features of this disease and developing newer strategies of therapy which are hypothesis-driven. Dr. Rai is an active member of the International Workshop on CLL (iwCLL) and Dr. Keating s Global CLL Foundation. He is an active member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and the American Society of Hematology (ASH). In 2006, Dr. Rai served as the President of ASH. He was the recipient of ASCO s David Karnofsky Memorial Award in 2012. In 2013, Dr. Rai was honored with the iwCLL David Galton award. In 2014 he was presented with ASH s Wallace H. Coulter Lifetime Achievement Award. Dr. Rai is the Joel Finkelstein Cancer Foundation Professor of Medicine, and Professor of Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell School of Medicine and Professor of Medicine at the Feinstein Institute for Medical Research, Manhasset, NY. Dr. Rai is rated as a Distinguished provider by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Leukemia, and Richter Syndrome.